33 results about "Colon inflammation" patented technology

The invention discloses a folic acid modified active oxygen response type sodium alginate nano-carrier and application thereof, and the preparation method comprises the following steps: firstly synthesizing-Se-Se-FA: stirring dicyclohexylcarbodiimide, 4-dimethylaminopyridine, dimethyl sulfoxide / pyridine, a double-selenium fragment and folic acid at room temperature for 18-22 hours in an argon environment; and carrying out acetone precipitation, centrifugation, washing, rotary evaporation concentration and freeze-drying. The preparation method comprises the following steps: preparing an ALG-Se-FA carrier, stirring sodium alginate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and hydroxysuccinimide in a 2-morpholinoethanesulfonic acid buffer solution, adding DMSO, dissolving a double-selenium fragment and a-Se-Se-FA fragment in DMSO and deionized water, adding the dissolved double-selenium fragment and-Se-Se-FA fragment into a system, stirring, dialyzing, and freeze-drying to obtain the product. According to the carrier, a double-selenium bond ROS response unit and folic acid targeting molecules are introduced through covalent bonds, astaxanthin can be efficiently entrapped and protected, and after the carrier is stable in gastrointestinal environment and reaches a colitis disease part, high ROS level can be responded, and intelligent drug slow release is achieved through folic acid receptor targeting.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

The invention discloses a composition for synergistically regulating intestinal flora and application thereof. The composition comprises the following components in parts by weight: 10-80 parts of a cordyceps militaris extract, 2-40 parts of quercetin, 5-50 parts of prebiotics and 5-80 parts of nucleotide. The compositions provided by the invention supplement each other, have a synergistic effect, are compounded according to a scientific proportion, can improve the diversity of intestinal microorganisms of mice and the abundance of species, and can significantly improve intestinal inflammation symptoms in a mouse colitis model.

The invention discloses an ROS responsive hydrogel delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The hydrogel delivery system is prepared from sulfur-doped ginger carbon dots (SGCDs) and an ROS (reactive oxygen species) responsive sulfhydrylation hyaluronic acid (HS) hydrogel matrix, the SGCDs have excellent antioxidant and anti-inflammatory activity, and can be used for clearing ROS and simulating SOD and CAT enzyme functions; the HS hydrogel matrix triggers gelling in an inflammation part high ROS environment, and targeted drug release and colitis part retention are achieved. Through the synergistic effect of the SGCDs and the HS hydrogel matrix, the delivery system can efficiently remove ROS, promote polarization of macrophages from M1 type to M2 type, up-regulate an anti-inflammatory factor IL-10, down-regulate proinflammatory factors TNF-alpha, IL-1beta and IL-6, repair Occludin and remodel the intestinal flora homeostasis.

The invention discloses a pharmaceutical composition for improving or treating ulcerative colitis as well as a preparation method and application thereof. The pharmaceutical composition is prepared from the following raw materials: radix puerariae, radix scutellariae, rhizoma coptidis, honey-fried licorice root, baked ginger and humifuse euphorbia herb. Research on a classic famous prescription, namely, the radix puerariae, radix scutellariae and ligation decoction, for treating damp-heat downward benefiting discovers that the modified prescription of the radix puerariae, radix scutellariae and ligation decoction has a good treatment effect on ulcerative colitis. According to the invention, reverse and assistant traditional Chinese medicines capable of warming middle energizer and dysentery are added into the group medicines capable of clearing heat and promoting diuresis, so that the modified prescription of the radix puerariae, radix scutellariae and lianghua decoction is formed through improvement, and research shows that the modified prescription can obviously improve the colitis symptom of acute colitis. In addition, the preparation method of the pharmaceutical composition also has the characteristics of rapidness, simplicity, convenience and easiness in operation.

The present application relates to the technical field of biological medicine engineering, and provides application of RBFOX2 inhibitor in treatment of inflammatory bowel disease, and particularly relates to the role of interfering RNA or antisense oligonucleotide or recombinant expression vector targeting RBFOX2 coding sequence in preparation of products for treating colitis and its related symptoms and / or other complications, and also relates to corresponding recombinant vectors or pharmaceutical compositions. The RBFOX2 inhibitor can effectively reduce the level of proinflammatory cytokines, inhibit the activation of macrophages, has effective application value in relieving and treating colonic inflammation and other symptoms and / or other complications of inflammatory bowel disease, provides a new target for treatment of inflammatory bowel disease, and has wide clinical application prospect.

The invention discloses mucoprotein nano-selenium gas motor hydrogel as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method of the mucoprotein nano-selenium gas motor hydrogel comprises the following steps: adding a carbonyl compound and selenite into an emulsifier solution, and adding a reducing agent for mixing reaction to obtain a nano-selenium gas motor, oxidized mucoprotein and the nano-selenium gas motor are mixed, then a cross-linking agent is added, the oxidized mucoprotein is subjected to a cross-linking reaction to form gel, and the mucoprotein nano-selenium gas motor hydrogel is obtained. The mucoprotein nano-selenium gas motor hydrogel is constructed by wrapping a gas motor into a mucoprotein hydrogel delivery system, the mucoprotein nano-selenium gas motor hydrogel can be specifically delivered to a colitis disease part through rectal administration, and meanwhile, the safe and controllable release and mucous membrane protection effects of the nano-selenium gas motor are realized; therefore, a new thought is provided for treating enteritis.

The invention relates to an application of an active peptide LLAPP in preparation of medicines for preventing and / or treating ulcerative colitis, cerebral ischemia and / or myocardial ischemia. According to the present invention, the LLAPP administration UC mouse animal experiment and the lipopolysaccharide (LPS) stimulation RAW264.7 cell experiment verify that the LLAPP can effectively relieve the ulcerative colitis, the cerebral ischemia and the myocardial ischemia symptoms, can be used as the ulcerative colitis, the cerebral ischemia and the myocardial ischemia treatment drug, can significantly improve the colitis symptoms, can alleviate the cerebral ischemia and myocardial ischemia injury, and can be used as the drug for treating the ulcerative colitis, the cerebral ischemia and the myocardial ischemia injury. Good development and application prospects are realized.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention belongs to the field of biomedicine, specifically relating to small interfering RNA (sRNA) targeting the TNF-α gene; it includes a sense strand and an antisense strand; the sense strand and / or the antisense strand has a length ranging from 19 to 25 nucleotides, and the antisense strand is inversely complementary to a segment on the target gene. Furthermore, it achieves drug delivery of the small interfering RNA through a specific target gene, enabling precise drug targeting at the site of colonic inflammation, enhancing the therapeutic effect of IBD without causing systemic immunosuppression, thus providing a more precise and efficient gene regulation tool.

The invention discloses a manganese-doped carbon dot and a preparation method and application thereof.The preparation method comprises the steps that citric acid is dissolved in deionized water, then MnCl2. 4H2O, ethanediamine and N-acetylcysteine are sequentially added and fully dissolved, and a hydrothermal reaction is conducted to obtain the small-particle-shaped manganese-doped carbon dot. According to the invention, the inorganic substance MnCl2. 4H2O which is widely anti-inflammatory and anti-oxidation is utilized to participate in the preparation of the carbon dots through a simple hydrothermal synthesis method, and the obtained manganese-doped carbon dots have the advantages of excellent multi-enzyme activity, good biocompatibility and the like, and have good application prospects in the aspects of inflammatory enteritis, colitis recovery and the like.

The present application relates to the technical field of microorganism, in particular to a leuconostoc lactis with good probiotic characteristics and application thereof in preparation of drugs for preventing and treating inflammatory bowel disease, and the leuconostoc lactis (Leuconostoc lactis) LL271 provided by the present application is preserved in China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 25974.The strain has good acid tolerance, bile salt tolerance, self-aggregation ability, hydrophobicity and other probiotic characteristics such as the ability to inhibit common human pathogenic microorganisms; meanwhile, the strain can improve intestinal inflammation, has prevention and treatment effects on inflammatory bowel disease, has high biological safety, can be used as probiotic preparation for relieving inflammatory bowel disease, improving intestinal mucosal injury and colon inflammation, provides a new strategy for preventing and treating inflammatory bowel disease, and has a potential clinical application prospect.

The application belongs to the technical field of microorganisms, and discloses Lactobacillus fermentum (L.f) LFSJ001 and application thereof in preparation of products for preventing or treating ulcerative colitis. The Lactobacillus fermentum LFSJ001 is independently isolated and identified. It is found through the use of DSS to construct a mouse colitis model that the Lactobacillus fermentum LFSJ001 combined with 5-Aminosalicylic Acid (5-ASA) can enhance the improvement of 5-ASA on the symptoms of colitis, including multiple indexes such as disease activity index, colon injury, and spleen index. It can be seen that the Lactobacillus fermentum LFSJ001 can be used as a combined drug of 5-ASA, enhance the efficacy of 5-ASA, inhibit the occurrence and development of ulcerative colitis, and improve the intestinal barrier. The application provides a new diagnosis and treatment direction and strategy for the prevention and treatment of ulcerative colitis.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

The application provides a lactobacillus plantarum DX7 and a method and application thereof for producing indole lactic acid, relates to the field of food microbial technology, and the lactobacillus plantarum DX7 has been preserved in the Guangdong Microbial Culture Collection Center on June 12, 2025, and the preservation number is GDMCC NO.66498. The lactobacillus plantarum DX7 in the application is significantly activated under the stimulation of deep-line walnut inner seed coat polyphenol, and can efficiently convert tryptophan into ILA. Experimental results show that the ILA yield of the strain reaches 217.56 mu g / mL. Moreover, the strain and deep-line walnut inner seed coat polyphenol can significantly relieve the colon inflammation symptoms of a DSS-induced colon inflammation mouse by gavage. The application not only provides a new strategy for efficient biological preparation of the functional component ILA, but also provides a basis and potential solution for dietary intervention of inflammatory bowel disease.

The present application relates to the field of medicine, in particular to a nano delivery system of protopanaxatriol targeting Twist1-Ku70-Sirt1 complex and application of the nano delivery system in treatment of colon inflammation related colorectal cancer, the nano delivery system comprising: (a) protopanaxatriol nanocrystal; (b) lipoic acid modified chitosan; and (c) crosslinking agent; wherein the average particle size of the protopanaxatriol nanocrystal is 100-200 nm; the modification degree of the lipoic acid modified chitosan is 15-25%; the crosslinking agent is sodium tripolyphosphate; and the average particle size of the nano delivery system is 300-500 nm, the solubility and bioavailability of protopanaxatriol are significantly improved by preparing protopanaxatriol into nanocrystal.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

This invention discloses a nanoemulsion gel containing Sichuan pepper volatile oil, its preparation method, and its application. The Sichuan pepper volatile oil nanoemulsion gel of this invention comprises a core layer and an encapsulation layer. The core layer is a nanoemulsion loaded with Sichuan pepper volatile oil, and the encapsulation layer is a carboxymethyl chitosan-sodium alginate composite hydrogel. The composite hydrogel forms a three-dimensional network structure through calcium ion cross-linking, encapsulating the Sichuan pepper volatile oil-loaded nanoemulsion within it. This invention prepares Sichuan pepper volatile oil into a nanoemulsion, significantly improving its water solubility and chemical stability, and reducing degradation in the gastrointestinal tract after oral administration. Further encapsulation with the carboxymethyl chitosan-sodium alginate composite hydrogel utilizes the pH sensitivity and colonic enzyme responsiveness of the composite hydrogel to reduce drug release in the stomach and small intestine, allowing the drug to degrade and release upon reaching the colon, thus increasing drug accumulation at sites of colonic inflammation. This solves the problems of poor targeting and low bioavailability of Sichuan pepper volatile oil.

The invention belongs to the technical field of aromatic hydrocarbon receptor ligands, and particularly relates to an AHR ligand 5-methoxy-2-methyl-3-indoleacetic acid and application thereof. According to the invention, a compound 5-methoxy-2-methyl-3-indoleacetic acid (MMIA) is used as an aromatic hydrocarbon receptor (AHR) ligand, and the application of the MMIA in the aspects of enhancing the stability of the AHR, promoting the AHR to enter a cell nucleus, relieving colitis and the like is disclosed. The result of the embodiment shows that the MMIA can be specifically combined and activate the AHR; mMIA gavage treatment can play an anti-inflammatory role and effectively relieve colitis symptoms. AHR is a key molecule for regulating and controlling the steady state of the intestinal tract, can inhibit proinflammatory pathways such as NF-kappa B and the like, reduce secretion of proinflammatory factors such as IL-6 and TNF-alpha, and also can repair damaged mucosa, restore the integrity of the intestinal barrier and improve related symptoms of the colitis from the source.

The present application relates to the field of microbial technology, and particularly relates to a bacterium El1405 and application thereof in bacteriostasis and anti-inflammation. The bacterium has a preservation number of CGMCC No.31231. The application includes bacteriostasis and anti-inflammation, and the microorganism includes one or more of Listeria monocytogenes, Staphylococcus aureus, Salmonella typhimurium or Escherichia coli. The bacterium can relieve various infection symptoms caused by Salmonella infection, and shows potential in preparation of a drug for treatment and / or prevention of infection of pathogenic bacteria such as Salmonella. The bacterium can also effectively relieve inflammatory bowel disease, reduce intestinal mucosal damage and colon inflammation symptoms, and provide a new strategy for prevention and treatment of inflammatory bowel disease, and has potential clinical application prospect.

The application is a colon-targeting lipid nanoparticle based on ginsenoside Rg3, a calcium alginate microsphere thereof and application thereof in treating ulcerative colitis, and belongs to the technical field of new excipients and new dosage forms of pharmaceutical preparations, and particularly relates to an oral colon-targeting delivery system for treating ulcerative colitis. The system replaces cholesterol in traditional lipid nanoparticles with ginsenoside Rg3, constructs lipid nanoparticles capable of efficiently loading TNF-alpha siRNA, and effectively improves the targeting property and lysosome escape ability of the lipid nanoparticles on inflammatory macrophages. In order to further realize colon-specific delivery, the above-mentioned lipid nanoparticles are loaded in a pH-responsive calcium alginate microsphere, so that the drug is kept stable in the upper gastrointestinal tract and is released in a responsive manner in the colon. Pharmacodynamic studies show that the drug delivery system can significantly relieve the symptoms of colitis, effectively silence the expression of TNF-alpha, repair the intestinal barrier, and regulate the intestinal microbiota. The application provides a safe and efficient new strategy for solving the problems of poor gastrointestinal stability and low targeting efficiency of oral delivery of nucleic acid drugs.

The invention discloses a preparation method and application of targeted colon nano-micelles for controlling and releasing curcumin through ROS response, and belongs to the technical field of intestinal medical materials. The targeted colon nano-micelle is composed of hyaluronic acid on a hydrophilic outer layer, vitamin E succinate on a hydrophobic inner core, thioketal and curcumin, hyaluronic acid and vitamin E succinate are connected through thioketal to form a hyaluronic acid-vitamin E succinate thioketal (VTH) micelle, and curcumin is coated through micelle self-assembly. Through innovative structural design, efficient loading of curcumin, active targeting enrichment of a colitis disease part and ROS-responsive precise drug release are realized, excellent biocompatibility, anti-inflammatory performance, anti-oxidation performance and antibacterial performance are achieved, the problems of low bioavailability, poor targeting performance and insufficient release control precision of drugs in treatment of ulcerative colitis are effectively solved, and the preparation method is suitable for industrial production. And a novel treatment strategy with high efficiency and low toxicity is provided for ulcerative colitis.

The application discloses a hydrogen sulfide responsive carbon monoxide donor molecule, a preparation method and application thereof. The hydrogen sulfide responsive carbon monoxide donor molecule has the structure shown in the following formula: wherein R1, R2, R3 and R4 are independently selected from an electron-withdrawing group, an electron-donating group or a hydrogen atom, and X is selected from O or the application provides a hydrogen sulfide responsive carbon monoxide donor molecule, which is designed in structure, acyloxy diene-Fe(CO)3 is selected as a carbon monoxide releasing unit, and an azido group is selected as a hydrogen sulfide responsive unit; the donor molecule formed by the two units has hydrogen sulfide responsiveness, can release carbon monoxide in the presence of hydrogen sulfide, can adjust the hydrogen sulfide response rate of the donor material and the release rate of carbon monoxide, and can further realize the treatment of colon inflammation and the inhibition of colorectal cancer.

The invention discloses application of enzyme powder prepared from bamboo shoots to improvement of ulcerative colitis, which comprises the following steps: S1, pretreatment culture and grouping: 72 C57BL / 6J male mice are adaptively fed for one week and then are divided into 6 groups, each group comprises 12 male mice, and the number of the male mice is 12; the method comprises the following steps: sequentially naming a normal control group (NC), a model group (DSS), a sulfasalazine group (SASP, 300 mg / kg), a square bamboo shoot enzyme low-dose group (CUJ-L), a square bamboo shoot enzyme medium-dose group (CUJ-M) and a square bamboo shoot enzyme high-dose group (CUJ-H); experimental data of mice show that the square bamboo shoot enzyme treatment can significantly improve colon shortening and DAI, improve weight loss and reduce the colitis symptom factor level; besides, the chimonobambusa quadrangularis ferment intervention improves the diversity and the structure of intestinal bacteria, the composition of intestinal microbiota is remodeled, the abundance of Firmicite gate is improved, and the abundance of Proteobacteria and Verrucomicrobiota, including Escherichia-Shiga, Akkermansia and other species, is reduced, and the application of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment intervention in the preparation of the chimonobambusa quadrangularis ferment is promoted. The intestinal metabolite and the intestinal flora have a close relationship; according to the method, 32 key metabolites are screened out through cecum metabolite analysis, and the key metabolites mainly relate to a Propionate metabolite metabolic pathway; the result shows that the square bamboo shoot enzyme has the potential of treating colitis.

The invention discloses application of Pediococcus pentosaceus PPSJ001 or peptidoglycan of the Pediococcus pentosaceus PPSJ001 in preparation of a product for preventing or treating intestinal inflammatory diseases, and the Pediococcus pentosaceus PPSJ001 is Pediococcus pentosaceus. The invention further discloses a preparation method of the Pediococcus pentosaceus PPSJ001 and a preparation method of the Pediococcus pentosaceus PPSJ001. According to the application research of the pediococcus pentosaceus PPSJ001 and peptidoglycan thereof in DSS-induced acute and chronic colitis mouse models, prophylactic or therapeutic gavage can obviously reduce the inflammation degree, relieve weight loss, restore the colon length and improve pathological damage of colon tissue. The pediococcus pentosaceus PPSJ001 can be used for promoting the expression of tight junction proteins ZO-1 and Occludin and mucoprotein Muc2 and improving the barrier function of intestinal mucosa. The key functional component is cell wall peptidoglycan, and the peptidoglycan can remarkably relieve the colitis disease in vivo, promote polarization of macrophages to a CD206 + M2 type in vitro and improve expression of anti-inflammatory related genes Arg1. Based on the unique functions, the pediococcus pentosaceus PPSJ001 or peptidoglycan thereof can be coordinated or complemented with other micro-ecological regulation means, and has a wide application prospect in medicine preparation.

The invention discloses insulin-loaded scutellaria baicalensis vesicle-like nanoparticles as well as a preparation method and application thereof, and the method comprises the following steps: mixing the scutellaria baicalensis vesicle-like nanoparticles and an insulin solution, and sequentially carrying out ultrasonic treatment, incubation and ultracentrifugation; and after the ultracentrifugation is finished, discarding the supernatant to remove free insulin, and retaining the precipitate, namely the insulin-loaded scutellaria baicalensis vesicle-like nanoparticles. The insulin-loaded scutellaria baicalensis vesicle-like nanoparticles prepared by the invention have a stable lipid bilayer structure in simulated gastrointestinal fluid, the biological activity of insulin is retained, the insulin-loaded scutellaria baicalensis vesicle-like nanoparticles can be orally taken for diabetes and diabetes complicated with colitis, a new strategy is provided for oral application of insulin, and the insulin-loaded scutellaria baicalensis vesicle-like nanoparticles have a better application prospect.

The application discloses a medicine compound for treating colon inflammatory diseases, which is compounded by acetylated Gastrodia elata gum and olsalazine; the mass ratio of the acetylated Gastrodia elata gum and the olsalazine is 50-150:20; the acetylated Gastrodia elata gum is a gelatinous white solid obtained by water extraction and alcohol precipitation of Gastrodia elata and reacted with acetic anhydride. The medicine compound can continuously release at a colon lesion site, has colon targeting and slow-release effects, can significantly reduce oxidation stress of colon cells, and has a synergistic effect in protecting colon cells, and has practical popularization and application value.

This invention belongs to the field of biotechnology, specifically relating to an oyster peptide that enhances intestinal barrier function and improves intestinal inflammation, its preparation method, and its applications. The oyster peptide provided by this invention can alleviate colitis symptoms such as weight loss, colon shortening, and edema in mice, reduce disease activity index (DAI) levels, and regulate the balance of oxidative stress and inflammatory factors. Furthermore, LC-MS / MS technology was used to analyze the peptide sequence of the oyster peptide. Through this precise analytical process, key small molecule peptides with significant effects on enhancing intestinal barrier function and improving intestinal inflammation were successfully screened. This discovery provides important evidence for a deeper understanding of the effects of oyster peptides on enhancing intestinal barrier function and improving intestinal inflammation, and also provides new ideas for subsequent drug development and clinical treatment.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of Atractylodes macrocephala ethyl acetate extract in the preparation of drugs for treating acute ulcerative colitis. The Atractylodes macrocephala extract is prepared by the following method: Atractylodes macrocephala is soaked overnight in a 60%–80% (v / v) ethanol solution, then refluxed at 90–110°C for 2–3 times, 1–3 hours each time, at a material-to-liquid ratio of 0.5–1.5:10–15 (kg / L), for 1–3 hours each time. The extracts are combined and concentrated to obtain a total extract. The total extract is then dissolved in water and extracted 2–3 times with an equal volume of ethyl acetate. The extracts are combined, concentrated, and dried to obtain the final extract. Animal experiments show that this extract can significantly improve the symptoms of DSS-induced ulcerative colitis in mice, reduce the disease activity index, alleviate pathological damage to colonic tissue, inhibit the expression of inflammatory factors, and protect intestinal barrier function, demonstrating good therapeutic potential.

The invention discloses a nano-composite for treating ulcerative colitis and a preparation method of the nano-composite, and belongs to the technical field of medicines. The nano-composite is a zeolite imidazate skeleton-8 nano-particle loaded by alpha-terpilenol, namely, an alpha TL (at) ZIF-8 nano-composite. The compound is obtained by encapsulating alpha-terpilenol in ZIF-8 nano particles formed by coordination of zinc ions and 2-methylimidazole. The preparation method comprises the following steps: mixing and reacting a zinc salt solution, a 2-methylimidazole solution and an alpha-terpilenol solution, and centrifugally washing to obtain a product. According to the nanocomposite, the water solubility and the stability of alpha-terpilenol are remarkably improved, and targeted release of a medicine at a colitis disease part is realized by utilizing the characteristic that ZIF-8 degrades in an acid environment, so that ulcerative colitis is efficiently treated, and meanwhile, the potential toxicity risk caused by whole body exposure is reduced.